Clinical Trials · NCT01567488
Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Enrollment
- 43
- Start date
- Jun 2011
- Locations
- 1 site, Spain
- Primary endpoint
- Percentage of patients with progression-free survival (PFS)